The new company, Accrete Health Partners, will act as an investment arm in the company’s digital health services interests and partnerships.

The new health system will have a combined footprint across Illinois, Wisconsin, North Carolina, South Carolina, Georgia and Alabama, serving approximately 5.5 million patients.

Biohaven is known as the company behind Nurtec ODT, a dual-acting migraine therapy approved for both the acute treatment and episodic prevention of migraines.

An overview for the coming January 2023 mandate to use clinical decision support for all advanced imaging orders.

The deal brings Integra’s more than 40,000 Medicaid members and network of care management teams to Anthem, which serves more than 118 million people.

Hello Heart, a digital therapeutics company that focuses on heart health, has raised $70 million in a Series D funding round.

With the shortage, which pertains specifically to all formulations and concentrations of GE Healthcare’s Omnipaque (iohexol), expected to last until mid-June, several organizations have alluded that conservation efforts are of critical importance.

All formulations and concentrations of GE Healthcare’s Omnipaque (iohexol) are expected to be in short supply until mid-June due to COVID lockdowns where the contrast is manufactured.